Abstract:Abstract Background Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin ( HTT ) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functions of many cellular proteins and subsequently jeopardizes important cellular machineries in major types of brain cells, including neurons, astrocytes, and microglia. The NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome, which comprises NLRP3, ASC, and caspase-1, is involved in the activation of IL-1β and IL-18 and has been implicated in various biological functions. Although the existence of the NLRP3 inflammasome in the brain has been documented, the roles of the NLRP3 inflammasome in HD remain largely uncharacterized. MCC950 is a highly selective and potent small-molecule inhibitor of NLRP3 that has been used for the treatment of several diseases such as Alzheimer’s disease. However, whether MCC950 is also beneficial in HD remains unknown. Therefore, we hypothesized that MCC950 exerts beneficial effects in a transgenic mouse model of HD. Methods To evaluate the effects of MCC950 in HD, we used the R6/2 (B6CBA-Tg[HDexon1]62Gpb/1J) transgenic mouse model of HD, which expresses exon 1 of the human HTT gene carrying 120 ± 5 CAG repeats. Male transgenic R6/2 mice were treated daily with MCC950 (10 mg/kg of body weight; oral administration) or water for 5 weeks from the age of 7 weeks. We examined neuronal density, neuroinflammation, and mHTT aggregation in the striatum of R6/2 mice vs. their wild-type littermates. We also evaluated the motor function, body weight, and lifespan of R6/2 mice. Results Systematic administration of MCC950 to R6/2 mice suppressed the NLRP3 inflammasome, decreased IL-1β and reactive oxygen species production, and reduced neuronal toxicity, as assessed based on increased neuronal density and upregulation of the NeuN and PSD-95 proteins. Most importantly, oral administration of MCC950 increased neuronal survival, reduced neuroinflammation, extended lifespan, and improved motor dysfunction in R6/2 mice. Conclusions Collectively, our findings indicate that MCC950 exerts beneficial effects in a transgenic mouse model of HD and has therapeutic potential for treatment of this devastating neurodegenerative disease.

Discovery of an Autophagy Inducer J3 to Lower Mutant Huntingtin and Alleviate Huntington’s Disease-Related Phenotype

Lowering mutant huntingtin by small molecules relieves Huntington’s disease symptoms and progression

Inhibition of HIPK3 by AST487 Ameliorates Mutant HTT-Induced Neurotoxicity and Apoptosis Via Enhanced Autophagy

mTOR inhibition in Q175 Huntington's disease model mice facilitates neuronal autophagy and mutant huntingtin clearance

HIPK3 Modulates Autophagy and HTT Protein Levels in Neuronal and Mouse Models of Huntington Disease

Effect of Praeruptorin C on 3-Nitropropionic Acid Induced Huntington'S Disease-Like Symptoms in Mice

Suppression of MAPK11 or HIPK3 Reduces Mutant Huntingtin Levels in Huntington's Disease Models

HAP40 Modulates Mutant Huntingtin Aggregation and Toxicity in Huntington’s Disease Mice

An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment

CGS21680 Attenuates Symptoms of Huntington's Disease in a Transgenic Mouse Model

Progress in studies of gene therapy for Huntington's disease

Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds

Systematic Uncovering of Multiple Pathways Underlying the Pathology of Huntington Disease by an Acid-Cleavable Isotope-Coded Affinity Tag Approach

HAP40 modulates mutant Huntingtin aggregation and toxicity in Huntington's disease mice

Dose-dependent reduction of somatic expansions but not Htt aggregates by di-valent siRNA-mediated silencing of MSH3 in HdhQ111 mice

Ellagic Acid Rescues Motor and Cognitive Deficits in the R6/2 Mouse Model of Huntington's Disease by Lowering Mutant Huntingtin Protein.

Blocking the Association of HDAC4 with MAP1S Accelerates Autophagy Clearance of Mutant Huntingtin

Protective Effects of Antcin H Isolated from Antrodia cinnamomea Against Neuroinflammation in Huntington's Disease via NLRP3 Inflammasome Inhibition

Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease

Gastrodin Improves the Activity of the Ubiquitin–Proteasome System and the Autophagy–Lysosome Pathway to Degrade Mutant Huntingtin

A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington’s disease